Amid Aduhelm's rocky launch, Biogen eyes large-scale layoffs: report City of Hope to acquire Cancer Treatment Centers of America for a reported $390M Novartis works on pan-coronavirus pill, eyes 2022 human testing J&J celebrates nurses with a new campaign in wake of burnout plaguing the profession Philips clinches FDA clearance for patient monitors that garnered emergency OK amid pandemic ASH: Senti Bio's gene circuit CAR-NK cell therapy enhances cancer killing and safety in leukemia models Nanomedicine shrinks vascular lesions in mice and could pave path to new treatments Anthem-backed Hydrogen Health rolls out virtual primary care services for insurers, employers Amid consumer spinoff and CEO transition, Johnson & Johnson names new leadership team BD seals the deal to acquire UK-based surgical sealant maker Tissuemed Another Samsung Bioepis? Biocon, Viatris mull merging biosimilar businesses: report Bright Health banks $750M investment from Cigna Ventures, New Enterprise Associates Science, talent, money: Eir raises $138M VC fund to fill gap in Nordic life science scene Chan Zuckerberg Initiative to pour $3.4B over 10 years into AI, imaging and other tech to unravel biomedical challenges Featured Story | By Fraiser Kansteiner After the rocky launch of its controversial Alzheimer’s disease drug Aduhelm, Biogen is gearing up for layoffs, STAT News reports. Overall, the staff squeeze could slash expenses by $500 million to $750 million, STAT said. read more |
| |
|---|
|
| | The PerkinElmer Biotech Bundle is deployed via Amazon CloudFormation and provides the most advanced analytical package for drug discovery available today. Affordable and easy to get started. Learn more. |
Top Stories By Anastassia Gliadkovskaya The transaction will expand City of Hope’s portfolio and contribute not only to its cancer services but also to research and development. read more By Ben Adams Unlike some of its Big Pharma peers, Novartis has not been at the forefront of creating new vaccines and treatments against COVID. Now, however, it’s taking its massive R&D budget and targeting not just the current pandemic, but all coronaviruses. read more By Sharon Klahr Coey Nurses deserve more than just a “thank you” for all they contribute, but Johnson & Johnson knows that appreciation is a good place to start. Continuing the company’s 120 year commitment to the nursing profession, J&J launched a new digital and print campaign to celebrate nurses and the work they’ve done during the pandemic and beyond. read more By Andrea Park Over a year after doling out an emergency use authorization for a handful of Philips’ IntelliVue patient monitoring devices, the FDA is doubling down on the regulatory nod. read more By Angus Liu Selecting the right target to kill off cancer cells while sparing healthy cells has been challenging for companies developing off-the-shelf cell therapies. Now, Senti Bio has promising early data on its CAR-NK therapy, developed from the biotech’s gene circuit platform, in acute myeloid leukemia. read more By Kyle LaHucik University of Chicago researchers say their novel nanomedicine shrank vascular lesions in mice and stopped the progression of plaque buildup that leads to vascular diseases. The team is working to secure funding for a larger animal study and form a company to test the treatment in people. read more By Heather Landi Anthem-backed digital health solution Hydrogen Health is rolling out its virtual primary care service for self-insured employers and insurers. Hydrogen Health rolled out its services with Anthem this past summer and is now expanding to multiple Fortune 500 employers and large regional health plans, company executives said, with a plan to be live for an additional 10 million people by the end of 2022. read more By Kevin Dunleavy Less than a month after revealing a plan to spin its consumer health business off as a new publicly traded company, Johnson & Johnson has shed more light on its future by naming new members of its executive committee. read more By Andrea Park After chalking up half a dozen tuck-in acquisitions throughout its fiscal year 2021—which ended Sept. 30—BD seems poised to outdo itself in 2022. Its first two tuck-in acquisitions of fiscal year 2022 came in rapid succession over the course of just the past week. read more By Angus Liu Samsung Bioepis represents the marriage of an Asian company and a Western drugmaker with a focus on biosimilars. Now, two other players are reportedly considering a similar merger. read more By Paige Minemyer Insurtech startup Bright Health has secured a $750 million capital investment that includes funding from Cigna Ventures. read more By Nick Paul Taylor The Nordic life sciences scene is getting an injection of cash. Led by centers such as the Karolinska Institutet and Copenhagen University, the region leads the way in research in the EU by many metrics but has traditionally lacked the vibrant VC scene needed to build large numbers of biotechs. Eir Ventures wants to help change that. read more By Andrea Park Five years into its lofty goal of funding projects to “cure, prevent or manage all disease within our children’s lifetime,” the Chan Zuckerberg Initiative’s Biohub is getting a major boost. read more |
